FindTrial
Sign In

Photography and measuring blood level of markers in patients with patchy hair loss

A clinico-dermoscopic profile and evaluation of association of TNF-alpha in patients with alopecia areata

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/02/011856
Enrollment
40
Registered
2018-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with patchy hair loss that is alopecia areata

Interventions

None listed

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: CASES 1. All patients with patchy hair loss diagnosed as alopecia areata either clinically or following biopsy irrespective of age and sex. 2. All patients of alopecia areata not systemically treated with corticosteroid or immunosuppressants. CONTROLS 1. Age and sex matched individuals without alopecia areta.

Exclusion criteria

Exclusion criteria: 1. Patients not consenting to participate in the study. 2. Patients who have received any topical or systemic treatment during the last two months will be excluded. 3.All Known cases of inflammatory diseases or autoimmune diseases will be ruled out.

Design outcomes

Primary

MeasureTime frame
Increased level of tnf-alpha in patients with alopecia areata Find out dermoscopic features in patiets with alopecia areataTimepoint: Increased level of TNF-alpha will be assessed in a period of 18 months—

Secondary

MeasureTime frame
Dermoscopic features include white dotsTimepoint: SALT score will be done within a period of 18 months—

Countries

India

Contacts

Public ContactDr Mahadevappa

K S Hegde medical academy

drgirishbs@gmail.com9448824934

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026